Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Equities research analysts at Leede Financial dropped their FY2025 EPS estimates for Cipher Pharmaceuticals in a report issued on Friday, November 8th. Leede Financial analyst D. Loe now expects that the company will earn $0.93 per share for the year, down from their prior forecast of $1.02. Leede Financial has a "Hold" rating on the stock. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals' FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.14 EPS.
A number of other research firms have also recently issued reports on CPH. Stifel Nicolaus decreased their price target on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 12th.
Read Our Latest Research Report on CPH
Cipher Pharmaceuticals Stock Performance
Shares of TSE CPH traded down C$0.90 during midday trading on Monday, reaching C$12.98. The company had a trading volume of 93,224 shares, compared to its average volume of 47,306. The business's 50-day simple moving average is C$16.19 and its 200 day simple moving average is C$12.27. The stock has a market cap of C$332.16 million, a P/E ratio of 10.41 and a beta of 1.20. Cipher Pharmaceuticals has a 1 year low of C$5.03 and a 1 year high of C$19.69. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33.
Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last posted its earnings results on Thursday, November 7th. The company reported C$0.01 EPS for the quarter, missing analysts' consensus estimates of C$0.03 by C($0.02). The firm had revenue of C$14.15 million for the quarter, compared to analysts' expectations of C$13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Featured Articles
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
